Infliximab is a monoclonal antibody that blocks tumor necrosis factor alpha (TNFα), a major pro-inflammatory cytokine involved in chronic inflammatory diseases. By binding to both soluble and membrane-bound forms of TNFα, it prevents receptor interaction and reduces inflammatory signaling. This leads to decreased production of pro-inflammatory cytokines, reduced immune cell migration, inhibition of tissue-degrading enzymes, and overall control of inflammatory activity across various human cells including fibroblasts, lymphocytes, and endothelial cells.
Therapeutic drug monitoring (TDM) plays an important role in maintaining safe and effective concentrations of biologics like infliximab. TDM helps optimize dosing, improve compliance, minimize drug-drug interactions, and reduce toxicity. With the expiration of exclusivity periods for first-generation biologics, biosimilars are being introduced as alternatives. While designed to be highly similar in safety and efficacy, biosimilars cannot be exact copies due to complex manufacturing processes. Even small variations may influence immunogenicity and patient responses, underscoring the need for careful monitoring and evaluation of biologics and their biosimilars.
This product is manufactured in Turkey by Matriks Biotek.
| Size | 1 x 96 Well |
| Sensitivity | 156 ng/mL |
| Dynamic Range | cut-off |
| Incubation Time | 95 minutes |
| Sample Type | Serum, Plasma |
| Storage | 2-8°C |